Regulated cell death in cerebral infarction: a switch-aware framework from molecular mechanisms to targeted therapy
Authors:
Open Access
- 10 November 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1996341
Abstract
Background: Cerebral infarction remains a leading cause of death and long-term disability. Although reperfusion therapy has transformed early management, its benefit is limited by narrow time windows, and most neuroprotective monotherapies have failed in translation. Rather than isolated endpoints, apoptosis, necroptosis, pyroptosis, ferroptosis and autophagy-related processes form a dynamically interconnected network; cuproptosis remains an exploratory candidate. Methods: This narrative synthesis (not a systematic/meta-analysis) drew on primary research and authoritative nomenclature sources on the major regulated cell death modalities in cerebral ischemia/reperfusion, retrieved from PubMed, Embase, and Web of Science through August 2026. The search was not pre-registered, and no formal risk-of-bias assessment was performed. Results: Post-ischemic cell death is organized around three convertible molecular switch hubs—caspase-8/RIPK, NCOA4ferritinophagy, and Nrf2 — with gasdermin-D (GSDMD)-mediated pyroptosis as a downstream effector. These hubs map onto the ischemic core, penumbra, and reperfused territory over 0–72 h, and their interconversion helps explain the limited efficacy of single-executor monotherapies. We further assess biomarkers and pharmacological interventions, and extend the framework through the gut-brain axis, where intestinal barrier dysfunction and dysbiosis prime the same central NLRP3, RIPK, and Nrf2 switches. Cuproptosis is retained only as a hypothesis-generating candidate. Clinically meaningful neuroprotection will require mechanism-based, time-and compartment-specific combination strategies. Modality-specific composite biomarker panels paired with time-sensitive therapies offer the most tractable route to patient stratification; the gut-derived input requires prospective validation. Conclusion: Framing post-ischemic cell death through convertible switches reframes neuroprotection as a problem of network timing and patient stratification. This switch-aware framework is prospective and falsifiable, generating testable hypotheses for future preclinical and clinical studies.Keywords
This publication has 34 references indexed in Scilit:
- Targeting Ferroptosis and Necroptosis to Treat StrokeNeurochemical Research, 2026
- Chrysophanol exerts neuroprotection against cerebral ischemia- reperfusion injury by regulating IκBα-stabilized MLKL via ZNF460-TRAF6 axisPhytomedicine, 2026
- Non-apoptotic Regulated Cell Death Mechanisms in Sepsis and their Therapeutic PotentialInflammation, 2026
- Iron promotes both ferroptosis and necroptosis in the early stage of reperfusion in ischemic strokeGenes & Diseases, 2024
- Molecular mechanisms and therapeutic strategies for ferroptosis and cuproptosis in ischemic strokeBrain, Behavior, & Immunity - Health, 2024
- Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet Neurology, 2021
- Methylene blue post-treatment improves hypoxia-ischemic recovery in a neonatal rat modelNeurochemistry International, 2020
- NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosisRedox Biology, 2019
- Age‐related changes in the gut microbiota influence systemic inflammation and stroke outcomeAnnals of Neurology, 2018
- Different Strokes for Different Folks: The Rich Diversity of Animal Models of Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 2010